Which of the following ethical dilemmas occurs when organization members are forced to participate in an OD intervention?

1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for good clinical practice E6(R1) June. 1996. [Last accessed on 2011 Apr 19]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf .

2. Berry IR. New York: Marcel Dekker; 2005. The Pharmaceutical Regulatory Process. [Google Scholar]

3. Lee C, Lee LH, Wu CL, Lee BR, Chen ML. Florida: CRC Press, Taylor and Francis Groups; 2006. Clinical Trials of Drugs and Biopharmaceuticals. [Google Scholar]

4. The Nuremberg code (1947) [Last accessed on 2011 Apr 19];Br Med J. 1996 313:1448. Available from: http://www.cirp.org/library/ethics/nuremberg . [Google Scholar]

5. World Medical Association declaration of Helsinki. Ethical principles for medical research involving human subjects. [Last accessed on 2011 Apr 20]. Available from: http://www.ohsr.od.nih.gov/guidelines/helsinki.html .

6. The Belmont Report ethical principles and guidelines for the protection of human subjects of research. The National Commission for the protection of human subjects of biomedical and behavioral research; April 18. 1979. [Last accessed on 2011 Apr 20]. Available from: http://www.ohsr.od.nih.gov/guidelines/belmont.html .

7. Geneva: Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO); 2002. [Last accessed on 2011 Apr 20]. International ethical guidelines for biomedical research. Available from: http://www.nccr.gov.my/index.cfm?menuid=23 and parentid=17 . [Google Scholar]

8. Research involving children under the age of 18. [Last accessed on 2011 Apr 20]. Available from: http://www.belmont.edu/irb/instructions/Consent.html#Children .

9. CFR-Code of Federal Regulations Title 21; Part 50-Protection of Human Subjects. Short form written consent document. [Last accessed on 2011 Apr 21]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.27 .

10. Investigator responsibilities-Protecting the rights safety, and welfare of study subjects 2009 October. [Last accessed on 2011 Apr 21]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM187772.pdf .

11. Informed consent. [Last accessed on 2011 Apr 22]. Available from: http://www.hhs.gov/ohrp/archive/irb/irb_chapter 3.htm#e2 .

12. Niazi SK. USA: Informa Healthcare; 2007. Handbook of Bioequivalence Testing. [Google Scholar]

13. Guidelines for writing informed consent documents. OHSR Information Sheets/Forms 2006 December. [Last accessed on 2011 Apr 26]. Available from: http://www.ohsr.od.nih.gov/info/sheet6.html .

14. Informed Consent Process Flow. [Last accessed on 2011 Apr 27]. Available from: https://www.ctnbestpractices.org/resources/study-patient-management/informed-consent/Informed_Consent_Process.pdf/view .

15. Waiver of Informed Consent. [Last accessed on 2011 Apr 29]. Available from http://www.irb.purdue.edu/waiveconsent.shtml .

16. Escobedo C, Guerrero J, Lujan G, Ramirez A, Serrano D. Ethical Issues with Informed Consent. [Last accessed on 2011 Apr 29]. Available from: http://www.cstep.cs.utep.edu/research/ezine/EzineEthicalIssueswithInformedConsent.pdf .

17. Jehovah's Witness ethics 2009 September 29. [Last accessed on 2011 Apr 30]. Available from: http://www.bbc.co.uk/religion/religions/witnesses/witnessethics/ethics_1.shtml .

18. Jehovah's Witnesses and Blood Transfusions. [Last accessed on 2011 May 2]. Available from: http://www.jwfacts.com/watchtower/blood.transfusions.php .

19. Gonzalez LE, Quinn GP, McIntyre J. Main Barriers to Participation. [Last accessed on 2011 May 4]. Available from: http://www.kon.org/urc/v9/gonzalez.html .

20. Child Assent Requirement 2010 January. [Last accessed on 2011 May 6]. Available from: http://www.nhlbi.nih.gov/childrenandclinicalstudies/terms_assent.php .

21. Ethical Principles for Researching Vulnerable Groups 2003 May. [Last accessed on 2011 May 7]. Available from: http://www.ofmdfmni.gov.uk/ethicalprinciples.pdf .

22. Levine RJ. Michigan: Urban and Schwarzenberg; 1981. The Ethics and Regulation of Clinical Research. [Google Scholar]

23. DeCosta A, D’souza N, Krishnan S, Chhabra MS, Shihaam I, Goswami K. Community based trials and informed consent in rural north India. J Med Ethics. 2004;30:318–23. [PMC free article] [PubMed] [Google Scholar]

24. Kharawala S, Dalal J. Challenges in conducting psychiatry studies in India. Perspect Clin Res. 2011;2:8–12. [PMC free article] [PubMed] [Google Scholar]

25. Gupta UC, Kharawala S. Informed consent in psychiatry clinical research: A conceptual review of issues, challenges, and recommendations. Perspect Clin Res. 2012;3:8–15. [PMC free article] [PubMed] [Google Scholar]

Page 2

Evolution of informed consent

September 3

OD Practitioners can face many obstacles during the OD process, and ethical compatibility with the client and sponsor is certainly one aspect that can lead to challenges.

The first obstacle of ethics is whether or not to even accept or decline working with a sponsor or organization. The personal or professional ethics of a client may not be the same as a practitioner’s. OD practitioners may sometimes let personal values stand in the way of good practice because of strong beliefs or biases.

A possible common ethical dilemma is that of misrepresentation. It can oftentimes occur if an OD practitioner overpromises results and also if in turn the client provides unrealistic goals and expectations. That is a scenario that does not provide trust and positive results for the client.  If OD practitioners attempt to take on an intervention and they are not equipped to do so or if a client wants to make changes but they are not ready, this is also misrepresentation and a situation that both parties should walk away from.

Data or technological use can be an area which ethical dilemmas arise. In the process of an intervention, data gathering is such a critical piece of ensuring that the project is on track and measures for goals are put into place. This data can also pull information to “tell the story” as to why things need to be improved for the client and where areas can change. If data is misused or calculated in a way where it can be misleading in order to benefit the OD practitioner, that can be damaging to the client in the long run and hurt the reputation of the OD practitioner.

Lastly, it is very easy to pull employees from client organizations into research (focus groups, interviews, surveys) without providing them a reason as to why they are being approached for the benefit of gathering what you need. OD practitioners must be upfront with each person in the process to share their intent so that people do not feel as if they were forced into something that they did not want to be included in, especially if some of the information is confidential.

It is human nature to be passionate about a topic or idea. The role of the OD practitioner is to do what is best for the client based on following a process, not what THEY FEEL is best. What works for one client may not work for another client. Everything must be done with the utmost ethical intention to provide the client the tools they need to succeed after the practitioner exits the intervention. The intent is not one of emotional attachment, no matter how hard that sounds.